JP Morgan Chase
AVTX icon

JP Morgan Chase’s Avalo Therapeutics AVTX Stock Holding History

JP Morgan Chase’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54K Buy
+2,800
New +$44.3K ﹤0.01% 6390

Other funds holding AVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase's AVTX Position: Q2 2026 in Review

JP Morgan Chase reduced its Avalo Therapeutics (AVTX) stake by 91% in Q2 2026, selling an estimated $2.79M and leaving 18,145 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #5308.

JP Morgan Chase first reported a position in AVTX in Q1 2019 and has held it in 26 quarters since. The position peaked at $2.71M in Q1 2026. 46 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • JP Morgan Chase held 18,145 shares of Avalo Therapeutics worth $350K as of Q2 2026.
  • JP Morgan Chase sold 176,246 Avalo Therapeutics shares in Q2 2026, an estimated $2.79M.
  • Avalo Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5308 holding.
  • JP Morgan Chase first reported a position in Avalo Therapeutics in Q1 2019 and has held it in 26 quarters since.
  • JP Morgan Chase's Avalo Therapeutics position peaked at $2.71M in Q1 2026.
  • 46 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.